|
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
Mar 2024 |
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
|
Lowering the boom on lower-risk myelodysplastic syndromes |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes |
Aug 2020 |
Cancer |
Myelodysplastic Syndromes (MDS) |
|
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial |
Jul 2024 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study |
Dec 2023 |
Blood Advances |
Aplastic Anemia |
|
Long term survivors in severe aplastic anemia: standard mortality rates now comparable to controls? |
Jul 2023 |
Haematologica |
Aplastic Anemia |
|
Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality |
Jul 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
Jul 2020 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
|
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
|
Is blood transfusion safe during the COVID-19 pandemic? |
Sep 2020 |
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
